X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc.（XFOR）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · XFOR · 截至 2025年9月30日
股东结构概览
41
机构持有人数
▼ 11 vs Q2
$46.69M
机构持仓总市值
▲ $41.36M vs Q2
94.32M
总流通股
freeFloat 60.87%
13.65M
13F 申报持股数
▲ 10.85M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
XFOR 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC biological products, (no diagnostic substances) | 2.44M | 32.87% | 32.87% | $8.33B | Nov 14, 2025 | ▲ 1.87M |
BVF INC/IL biological products, (no diagnostic substances) | 2.23M | 30.13% | 30.13% | $7.64B | Nov 14, 2025 | NEW |
NANTAHALA CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.23M | 30.06% | 30.06% | $7.62B | Nov 14, 2025 | NEW |
ROSALIND ADVISORS, INC. biological products, (no diagnostic substances) | 1.54M | 20.84% | 20.84% | $5.28B | Nov 13, 2025 | NEW |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 1.12M | 15.14% | 15.14% | $3.84B | Nov 14, 2025 | NEW |
STONEPINE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.06M | 14.25% | 14.25% | $3.61B | Nov 13, 2025 | NEW |
KINGDON CAPITAL MANAGEMENT, L.L.C. biological products, (no diagnostic substances) | 933.3K | 12.59% | 12.59% | $3.19B | Nov 14, 2025 | ▲ 700.0K |
STEMPOINT CAPITAL LP biological products, (no diagnostic substances) | 555.4K | 7.49% | 7.49% | $1.90B | Nov 14, 2025 | NEW |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 410.5K | 5.54% | 5.54% | $1.40B | Nov 7, 2025 | ▲ 178.6K |
BOOTHBAY FUND MANAGEMENT, LLC biological products, (no diagnostic substances) | 344.0K | 4.64% | 4.64% | $1.18B | Nov 14, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
9
增持
+2.98M 股11
新建仓
首次建仓10
减持
−209.2K 股9
清仓
完全退出净股数变化（前50家）
+2.77M
+2.98M / −209.2K
净新增持仓人
+1
新建 11 个 / 退出 9 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
XFOR 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
0
买入笔数
1
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
KIRSKE DAVID Chief Financial Officer | May 12, 2026 | Sale | 16,961 | $4.29 | $72.8K | 176.3K | Form 4 ↗ |
Bridger Gary director | Jan 1, 2026 | Award | 110,000 | $4.00 | $440.0K | 0 | Form 4 ↗ |
de Craecker Francoise director | Jan 1, 2026 | Award | 110,000 | $4.00 | $440.0K | 0 | Form 4 ↗ |
WYZGA MICHAEL S director | Jan 1, 2026 | Award | 110,000 | $4.00 | $440.0K | 0 | Form 4 ↗ |
Stewart Murray director | Jan 1, 2026 | Award | 110,000 | $4.00 | $440.0K | 0 | Form 4 ↗ |
Craig Adam R Executive Chairman | Oct 29, 2025 | Award | 2,329,154 | $1.42 | $3.31M | 2.33M | Form 4 ↗ |
Volpone John President | Oct 29, 2025 | Award | 2,329,154 | $1.42 | $3.31M | 2.33M | Form 4 ↗ |
KIRSKE DAVID Chief Financial Officer | Oct 29, 2025 | Award | 1,552,769 | $1.42 | $2.20M | 1.55M | Form 4 ↗ |
Craig Adam R Executive Chairman | Oct 23, 2025 | Purchase | 86,206 | $2.90 | $250.0K | 376.1K | Form 4 ↗ |
Volpone John President | Aug 12, 2025 | Award | 1,609,873 | $1.42 | $2.29M | 1.61M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
X4 Pharmaceuticals, Inc.（XFOR）主要由机构投资者持有，机构持股比例约为 14.5%。公司内部人员持股约 39.13%，散户及公众持股约占剩余的 46.39%。
X4 Pharmaceuticals, Inc. 最大机构股东为 BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC，截至 September 30, 2025 持有约 2.44 million 股，占总流通股的 32.87%。
目前共有 41 家机构持有 XFOR 股票，合计持仓市值约 $46,691,414，数据来源为最新 SEC 13F 申报。
常见问题
XFOR ownershipX4 Pharmaceuticals, Inc.（XFOR）主要由机构投资者持有，机构持股约 14.5%。最大股东为 BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC，持股比例 32.87%。内部人员持股约 39.13%。数据来源 SEC Form 13F，截至 September 30, 2025。